SNDX Q3 2024 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M

Gross Profit

$13M100.0% margin

Operating Income

-$90M-716.6% margin

Net Income

-$84M-673.0% margin

EPS (Diluted)

$-0.98

QoQ Revenue Growth

+257.1%

Cash Flow

Operating Cash Flow

-$62M

Free Cash Flow

-$62M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$426M

Total Liabilities

$59M

Stockholders' Equity

$366M

Cash & Equivalents

$133M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$0	—
Gross Profit	$13M	$0	—
Operating Income	-$90M	-$56M	-59.0%
Net Income	-$84M	-$51M	-64.5%